marimastat marimastat marimastat was a proposed antineoplastic drug developed by british biotech. it acted as a broad-spectrum matrix metalloproteinase inhibitor. marimastatclinical dataroutes ofadministrationby mouthatc codenonelegal statuslegal status development terminated? identifiers iupac name n--2--4- methyl-pentanamide cas number154039-60-8 ypubchem cid119031iuphar/bps5220drugbankdb00786 nchemspider106358 nuniid5eqv23tdschemblchembl279785 npdb ligand097 (pdbe, rcsb pdb)comptox dashboard (epa)dtxsid20165524 chemical and physical dataformulac15h29n3o5molar mass331.413 g·mol−13d model (jsmol)interactive image smiles o=c(no)(o)(c(=o)n(c(=o)nc)c(c)(c)c)cc(c)c inchi inchi=1s/c15h29n3o5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23h,7h2,1-6h3,(h,16,22)(h,17,20)(h,18,21)/t9-,10+,11-/m1/s1 nkey:ocsmotcmpxtdnd-ouaukwlosa-n n ny (what is this?) (verify) marimastat performed poorly in clinical trials, and development was terminated. this may be, however, a result of targeting cancer at too late of a stage. this is supported by the fact that mmp inhibitors have more recently been shown in animal models to be more effective in earlier stages of cancers. (effects of angiogenesis inhibitors on multistage carcinogenesis in mice. science 284, 808-812. bergers, g., javaherian, k., lo, k.-m., folkman, j., and hanahan, d. (1999)).